Publicly traded (RKV.V) company focused on the development of new cancer treatments based on novel DNA-damage response technologies.
Rakovina Therapeutics has raised $1.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Rakovina Therapeutics's investors include Red Thread Ventures.
Rakovina Therapeutics is headquartered in Vancouver, Canada.
Publicly traded (RKV.V) company focused on the development of new cancer treatments based on novel DNA-damage response technologies.
Rakovina Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rakovina Therapeutics — Funding & Investors." VCBacked, July 15, 2026, https://www.vcbacked.co/company/rakovina-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Rakovina Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/rakovina-therapeutics
{{cite web |title=Rakovina Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rakovina-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated